Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | PDE5A | O76074 | 2/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.33 |
| ▸ | PDE11A | Q9HCR9 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29653296 | 1.00 | NNMT (0.50) | NNMTPOLBTDP1CYP1A2KMT2A | |
| SCHEMBL321488 | 0.79 | POLB (0.52) | NNMTPOLBTDP1CYP1A2KMT2A | |
| SCHEMBL29957302 | 0.79 | MAPT (0.39) | NNMTCYP1A2ALDH1A1HTT | |
| SCHEMBL2725012 | 0.78 | POLB (0.38) | NNMTPOLBTDP1CYP1A2KMT2A | |
| SCHEMBL29955515 | 0.78 | NNMT (0.41) | NNMTPOLBTDP1CYP1A2KMT2A | |
| SCHEMBL29952969 | 0.78 | POLB (0.38) | NNMTPOLBTDP1CYP1A2KMT2A | |
| SCHEMBL29956451 | 0.78 | POLB (0.38) | NNMTPOLBTDP1CYP1A2KMT2A | |
| SCHEMBL16294781 | 0.78 | POLB (0.38) | NNMTPOLBTDP1CYP1A2KMT2A | |
| SCHEMBL31189712 | 0.75 | NNMT (0.46) | NNMTPOLBTDP1CYP1A2KMT2A | |
| SCHEMBL29952389 | 0.75 | POLB (0.36) | NNMTPOLBTDP1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118359538-A | Isoquinoline compound, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-4067355-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYME (DUB) INHIBITORS | Mission Therapeutics Limited (GB) | 2022-10-05 | — | — | EP | disclosed |
| WO-2022109492-A1 | PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS | GOSSAMER BIOSERVICES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| EP-3423454-B1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-25 | — | — | EP | disclosed |
| CN-107709322-B | Tricyclic compounds as anticancer agents | 百时美施贵宝公司 | 2021-05-07 | — | — | CN | disclosed |
| US-10662170-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-26 | — | — | US | disclosed |
| EP-3247705-B1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF AS NAMPT INHIBITORS | MILLENNIUM PHARM INC (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-3294739-B1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2019-07-31 | — | — | EP | disclosed |
| US-10323018-B2 | Quinazoline and quinoline compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-10195178-B2 | GPR40 agonists in anti-diabetic drug combinations | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-05 | — | — | US | disclosed |
| WO-2004099201-A1 | COMPOUNDS AS CRF1 RECEPTOR ANTAGONISTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-11-18 | — | — | WO | disclosed |
| EP-1368094-A4 | 4-(2-BUTYLAMINO)-2,7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-YL) PYRAZOLO- 1,5-A]-1,3,5-TRIAZINE, ITS ENANTIOMERS AND PHARMACEUTICALLY ACCEPTABLE SALTS AS CORTICOTROPIN RELEASING FACTOR RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20040014760-A1 | 4- (2-butylamino) -2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-YL) pyrazolo- [1,5-A] -1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands | GILLIGAN PAUL J (US) | 2004-01-22 | — | — | US | disclosed |
| EP-1368094-A1 | 4-(2-BUTYLAMINO)-2,7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-YL) PYRAZOLO- 1,5-A]-1,3,5-TRIAZINE, ITS ENANTIOMERS AND PHARMACEUTICALLY ACCEPTABLE SALTS AS CORTICOTROPIN RELEASING FACTOR RECEPTOR LIGANDS | Bristol-Myers Squibb Pharma Company (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030149059-A1 | Tetrahydropurinones and derivatives thereof as corticotropin releasing factor receptor ligands | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-08-07 | — | — | US | disclosed |
| US-20030125330-A1 | 4 - (2-butylamino) - 2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-yl) pyrazolo- [1,5-A] - 1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands | BRISTOL-MYERS SQUIBB PHARMA COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-07-03 | — | — | US | disclosed |
| US-20030119831-A1 | 3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-26 | — | — | US | disclosed |
| WO-2003043637-A1 | 3,7-DIHYDRO-PURINE-2,6-DIONE DERIVATIVES AS CRF RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2003-05-30 | — | — | WO | disclosed |
| WO-2003005969-A2 | TETRAHYDROPURINONES AS CORTICOTROPIN RELEASING FACTOR | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2002072202-A1 | 4-(2-BUTYLAMINO)-2,7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-YL) PYRAZOLO-[1,5-A]-1,3,5-TRIAZINE, ITS ENANTIOMERS AND PHARMACEUTICALLY ACCEPTABLE SALTS AS CORTICOTROPIN RELEASING FACTOR RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10195178-B2 | GPR40 agonists in anti-diabetic drug combinations | GPR119, GLP1R, GPR65 | NNMT 1998/4885POLB 4845/4885TDP1 4855/4885 |
| US-10323018-B2 | Quinazoline and quinoline compounds and uses thereof | NAMPT, NQO2, NNMT | NNMT 3/4885POLB 3408/4885TDP1 2867/4885 |
| US-20030149059-A1 | Tetrahydropurinones and derivatives thereof as corticotropin releasing factor receptor ligands | CRH, CRHR1, CRHR2 | NNMT 3072/4885POLB 4463/4885TDP1 2595/4885 |
| US-10662170-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | GPR119, GPR52, GPR65 | NNMT 2521/4885POLB 4667/4885TDP1 4447/4885 |
| US-20030125330-A1 | 4 - (2-butylamino) - 2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-yl) pyrazolo- [1,5-A] - 1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands | CRHR2, CRH, CRHR1 | NNMT 4773/4885POLB 4548/4885TDP1 3366/4885 |
| US-20030119831-A1 | 3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands | GPR119, CRHR1, CRH | NNMT 3054/4885POLB 1574/4885TDP1 622/4885 |
| US-20040014760-A1 | 4- (2-butylamino) -2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-YL) pyrazolo- [1,5-A] -1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands | CRHR2, CRH, CRHR1 | NNMT 4773/4885POLB 4548/4885TDP1 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.